[go: up one dir, main page]

WO2011156000A3 - Use of il-4/il-13 antagonists to treat eosinophilic disorders - Google Patents

Use of il-4/il-13 antagonists to treat eosinophilic disorders Download PDF

Info

Publication number
WO2011156000A3
WO2011156000A3 PCT/US2011/001050 US2011001050W WO2011156000A3 WO 2011156000 A3 WO2011156000 A3 WO 2011156000A3 US 2011001050 W US2011001050 W US 2011001050W WO 2011156000 A3 WO2011156000 A3 WO 2011156000A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
eosinophic
provides methods
disorders
eosinophilic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/001050
Other languages
French (fr)
Other versions
WO2011156000A2 (en
Inventor
Babatunde Otulana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aerovance Inc
Original Assignee
Aerovance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerovance Inc filed Critical Aerovance Inc
Publication of WO2011156000A2 publication Critical patent/WO2011156000A2/en
Anticipated expiration legal-status Critical
Publication of WO2011156000A3 publication Critical patent/WO2011156000A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides methods for treating eosinophic disorders, including eosinophic asthma, by administering compositions that act as antagonists to IL 4 and IL-13, in particular antisense, RNAi, antibody, and mutant human interleukin-4 (IL-4) antagonists. The invention also provides methods and kits for determining the major allele in certain SNPs in the IL-4 receptor α polypeptide (IL-4RA) as an indication of likely response to IL-4/IL-13 antagonist treatment.
PCT/US2011/001050 2010-06-07 2011-06-07 Use of il-4/il-13 antagonists to treat eosinophilic disorders Ceased WO2011156000A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39717410P 2010-06-07 2010-06-07
US61/397,174 2010-06-07

Publications (2)

Publication Number Publication Date
WO2011156000A2 WO2011156000A2 (en) 2011-12-15
WO2011156000A3 true WO2011156000A3 (en) 2013-11-07

Family

ID=45098570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/001050 Ceased WO2011156000A2 (en) 2010-06-07 2011-06-07 Use of il-4/il-13 antagonists to treat eosinophilic disorders

Country Status (1)

Country Link
WO (1) WO2011156000A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4011915T (en) 2012-08-21 2024-01-02 Regeneron Pharma Methods for treating or preventing asthma by administering an il-4r antagonist
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
MX2016013372A (en) * 2014-04-11 2017-01-26 Novartis Ag Methods of selectively treating asthma using il-13 antagonists.
EP3191513B1 (en) 2014-09-08 2020-06-24 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
AU2020315369A1 (en) 2019-07-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
JP2024536001A (en) * 2021-09-30 2024-10-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Treatment of asthma with reticulocalbin-3 (RCN3) variants and interleukin-4 receptor alpha (IL4R) antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010874A1 (en) * 2003-08-29 2009-01-08 Aerovance, Inc. Modified il-4 mutein receptor antagonists
US20090291981A1 (en) * 2008-05-23 2009-11-26 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein Inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090010874A1 (en) * 2003-08-29 2009-01-08 Aerovance, Inc. Modified il-4 mutein receptor antagonists
US20090291981A1 (en) * 2008-05-23 2009-11-26 Amira Pharmaceuticals, Inc. 5-Lipoxygenase-Activating Protein Inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BORISH, L.C. ET AL.: "Efficacy Of Soluble IL-4 Receptor For The Treatment Of Adults With Asthma", J ALLERGY CLIN IMMUNOL., vol. 107, no. 6, June 2001 (2001-06-01), pages 963 - 970 *
LECKIE, M.J. ET AL.: "Effects Of An Interleukin-5 Blocking Monoclonal Antibody On Eosinophils, Airway Hyper-Responsiveness, And The Late Asthmatic Response", THE LANCET, vol. 356, 23 December 2000 (2000-12-23), pages 2144 - 2148 *
UMHS ASTHMA QUALITY IMPROVEMENT STEERING COMMITTEE: "Quick Reference Charts For The Classification And Stepwise Treatment Of Asthma", ADAPTED FROM 2007 NHLBI GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ASTHMA EXPERT PANEL REPORT 3, 30 June 2008 (2008-06-30) *
YING, S. ET AL.: "Associations Between IL-13 And IL-4 (mRNA And Protein), Vascular Cell Adhesion Molecule-1 Expression, And The Infiltration Of Eosinophils, Macrophages, And T Cells In Allergen-Induced Late-Phase Cutaneous Reactions In Atopic Subjects", THE JOURNAL OF IMMUNOLOGY, vol. 158, no. 10, 10 February 1997 (1997-02-10), pages 5050 - 5057 *

Also Published As

Publication number Publication date
WO2011156000A2 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
WO2011156000A3 (en) Use of il-4/il-13 antagonists to treat eosinophilic disorders
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
WO2013033626A3 (en) Nkp30 receptor targeted therapeutics
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
IN2012DN06588A (en)
WO2012118750A3 (en) Biological markers and methods for predicting response to b-cell antagonists
TN2010000126A1 (en) Antibodies that bind il-4 and/or il-13 and their uses
NZ588853A (en) Compositions and methods for treating and diagnosing asthma
NZ756749A (en) Methods and compositions comprising purified recombinant polypeptides
WO2007082068A3 (en) Methods and compositions for treating asthma in human and non human primates
WO2012033987A3 (en) Anti-human folate receptor beta antibodies and methods of use
UA100262C2 (en) Inhibitors of protein tyrosine kinase activity
MX2008010807A (en) Thymic stromal lympho po i et in (tslp) antibodies and uses thereof.
MX2013008833A (en) Methods and compositons relating to inhibition of igf-1r.
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
MX2018009524A (en) Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use.
MY144906A (en) Human antibodies against il13 and therapeutic uses
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
MX2008013597A (en) Cxcl13 antagonists and their use for the treatment of inflammatory diseases.
TW200716171A (en) Methods for treating and preventing fibrosis
WO2009121847A3 (en) Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
PH12012502073A1 (en) Inhibitors of protein tyrosine kinase activity
WO2011160086A3 (en) Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
MX2009010633A (en) Cxcl13 antagonists and their use for the treatment of inflammatory diseases.
WO2008060814A3 (en) ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11792785

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03/06/2013)

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 13/02/2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11792785

Country of ref document: EP

Kind code of ref document: A2